Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy shifts atorvastatin production to India
Atorvastatin, a generic version of Pfizer’s Lipitor, is used to lower blood cholesterol levels. In addition, Ranbaxy has received the US Food and Drug Administration approval to market
Atorvastatin, a generic version of Pfizer’s Lipitor, is used to lower blood cholesterol levels. In addition, Ranbaxy has received the US Food and Drug Administration approval to market
The collaboration will enable both the companies to deliver end-to-end services from initial drug discovery through to early and late phase manufacturing. Under the alliance, Molecular Profiles will
The 3K3A-APC is a form of activated human Protein C whose molecular structure has been intentionally modified to remove the undesirable side effect of bleeding. ZZ Biotech chief
The primary outcome of the study which randomized 430 participants across three treatment arms placebo, 5mg or the currently marketed dose of 10mg of dalfampridine-ER, twice daily, was
ScripsAmerica’s manufacturer is expected to begin production of the RapiMed formulations and make the product available for distribution during the first quarter of 2013. ScripsAmerica CEO Bob Schneiderman
The company is seeking approval to manufacture and market Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets), the first ascending-dose, extended regimen oral contraceptive for the prevention of
Symbicort Turbuhaler is a combination product containing a long-acting ß2 agonist with a bronchodilating action that is the mainstay of drug-based COPD therapy, and an inhaled corticosteroid, which
The services include IT strategy and planning, electronic health record (EHR) implementation and optimization, and management consulting across a broad range of activities such as accountable care transformation.
Nexium (esomeprazole magnesium) is a prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD). Pfizer consumer healthcare president Paul Sturman said, "By working with
EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The 16-week study will enroll about 100 patients at multiple US clinical centers